ATE187069T1 - Hydroxylierte metaboliten und derivate von doxazosin gegen atherosklerose - Google Patents

Hydroxylierte metaboliten und derivate von doxazosin gegen atherosklerose

Info

Publication number
ATE187069T1
ATE187069T1 AT93301505T AT93301505T ATE187069T1 AT E187069 T1 ATE187069 T1 AT E187069T1 AT 93301505 T AT93301505 T AT 93301505T AT 93301505 T AT93301505 T AT 93301505T AT E187069 T1 ATE187069 T1 AT E187069T1
Authority
AT
Austria
Prior art keywords
derivatives
doxazosine
hydroxylated metabolites
against atherosclerosis
retarding
Prior art date
Application number
AT93301505T
Other languages
English (en)
Inventor
Samuel Siu-Ming Wong
Archie Calhoun Swindell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE187069T1 publication Critical patent/ATE187069T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/15—Details of package parts other than the semiconductor or other solid state devices to be connected
    • H01L2924/181—Encapsulation
AT93301505T 1992-04-01 1993-02-26 Hydroxylierte metaboliten und derivate von doxazosin gegen atherosklerose ATE187069T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86171492A 1992-04-01 1992-04-01

Publications (1)

Publication Number Publication Date
ATE187069T1 true ATE187069T1 (de) 1999-12-15

Family

ID=25336560

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93301505T ATE187069T1 (de) 1992-04-01 1993-02-26 Hydroxylierte metaboliten und derivate von doxazosin gegen atherosklerose

Country Status (17)

Country Link
US (1) US5543411A (de)
EP (1) EP0564093B1 (de)
JP (1) JPH0624989A (de)
KR (1) KR0137927B1 (de)
AT (1) ATE187069T1 (de)
AU (1) AU660359B2 (de)
CA (1) CA2092983C (de)
DE (1) DE69327128T2 (de)
DK (1) DK0564093T3 (de)
ES (1) ES2139624T3 (de)
GR (1) GR3032373T3 (de)
HU (1) HU225113B1 (de)
IL (1) IL105141A (de)
MX (1) MX9301824A (de)
NZ (1) NZ247307A (de)
PT (1) PT564093E (de)
ZA (1) ZA932307B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120302A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
IL120303A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
US20050165428A1 (en) * 2000-09-25 2005-07-28 Franco Kenneth L. Absorable surgical structure
US20020052572A1 (en) * 2000-09-25 2002-05-02 Kenneth Franco Resorbable anastomosis stents and plugs and their use in patients
ES2523432T3 (es) 2003-07-18 2014-11-25 Hamamatsu Photonics K.K. Chip semiconductor cortado

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB271997A (en) * 1926-04-16 1927-06-09 Morris Engines Coventry Ltd Improvements relating to the driving of cam or other auxiliary shafts in internal combustion engines
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent

Also Published As

Publication number Publication date
HUT65849A (en) 1994-07-28
NZ247307A (en) 1997-06-24
DK0564093T3 (da) 2000-03-27
EP0564093A1 (de) 1993-10-06
CA2092983C (en) 1996-12-31
CA2092983A1 (en) 1993-10-02
HU225113B1 (en) 2006-06-28
KR0137927B1 (ko) 1998-05-15
IL105141A0 (en) 1993-07-08
ZA932307B (en) 1994-09-30
PT564093E (pt) 2000-04-28
KR930021203A (ko) 1993-11-22
ES2139624T3 (es) 2000-02-16
DE69327128D1 (de) 2000-01-05
US5543411A (en) 1996-08-06
EP0564093B1 (de) 1999-12-01
JPH0624989A (ja) 1994-02-01
MX9301824A (es) 1994-02-28
GR3032373T3 (en) 2000-04-27
AU3562993A (en) 1993-10-07
IL105141A (en) 1998-10-30
HU9300947D0 (en) 1993-06-28
DE69327128T2 (de) 2000-04-20
AU660359B2 (en) 1995-06-22

Similar Documents

Publication Publication Date Title
NO914091D0 (no) Fremgangsmaate for fremstilling av hydroksylerte inhibitorer for hiv-reverstranskriptase
FI930970A0 (fi) Imidazolderivat med bifenylsulfonylurea- eller bifenylsulfonyluretansidokedja, foerfaranden foer framstaellning av dessa och anvaendning av dessa
FI961739A (fi) Amiinisuoloja klavulaanihapon valmistamiseksi
GR3035526T3 (en) Retroviral protease inhibitors.
UY24625A1 (es) Derivados de la 4-hidroxi-piperidina
DE3872333D1 (de) Doxazosin als antiatherosklerotikum.
FI931333A (fi) Foerfarande foer framstaellning av formoterol och liknande foereningar
ATE187069T1 (de) Hydroxylierte metaboliten und derivate von doxazosin gegen atherosklerose
NO930829L (no) Fremgangsmaate for fremstilling av klavulansyresalter
NO173816C (no) Fremgangsmaate ved oppbygging av en offshore-konstruksjon
FI921456A (fi) Substituerade 2',3'-didesoxi-5-trifluormetyluridiner, foerfaranden foer deras framstaellning och deras anvaendning i laekemedel
DE69519581T2 (de) Guanidylmethyl cyclohexancarbonsäure ester derivate
LV10088A (lv) Jauni fenilsulfonilakrilestera atvasinajumi
DK30284D0 (da) Pyrrolidiner
TR199701185A2 (xx) Sefalosporin piridinyum t�revleri.
FI922519A0 (fi) Menetelmä farmaseuttisesti käyttökelpoisten pilokarpiinijohdannaisten valmistamiseksi
FI922518A0 (fi) Menetelmä farmaseuttisesti käyttökelpoisten pilokarpiinijohdannaisten valmistamiseksi
KR940020673U (ko) 엘리베이터의 머신빔 고정구조
FI934035A0 (fi) Foerfarande och anordning foer stabilisering av en paoverkningsanordningstemperatur
FI925846A0 (fi) Anordning foer bestaemning av en roerlig pappersbanas formation och fiberorientering
KR950034188U (ko) 헤드드럼의 회전트랜스장치

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee